A new paradigm in cancer treatment
What is CAR-T?
Powerful therapy. Complex biology.
CAR-T cells can trigger a strong immune response. While this activity is central to their therapeutic effect, it can also lead to serious complications, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
These complications can vary in timing and severity, creating a need for close clinical monitoring.
A new paradigm in cancer treatment
Chimeric antigen receptor T-cell (CAR-T) therapy is a form of cellular immunotherapy that engineers T cells to recognize and attack cancer cells.
CAR-T therapy has become an important treatment option for several blood cancers, particularly for patients whose disease has returned or has not responded to prior treatment.
Where Axvia fits
Axvia is focused on one specific challenge within CAR-T care:
Identifying patients who may be at increased risk of severe ICANS earlier in their clinical course.